company background image
GTBP logo

GT Biopharma NasdaqCM:GTBP Stock Report

Last Price

US$4.43

Market Cap

US$6.0m

7D

16.3%

1Y

-68.2%

Updated

28 Mar, 2024

Data

Company Financials +

GTBP Stock Overview

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform.

GTBP fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

GT Biopharma, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for GT Biopharma
Historical stock prices
Current Share PriceUS$4.43
52 Week HighUS$18.00
52 Week LowUS$3.52
Beta0.58
1 Month Change7.26%
3 Month Change-42.09%
1 Year Change-68.23%
3 Year Change-97.95%
5 Year Change-97.06%
Change since IPO-100.00%

Recent News & Updates

Recent updates

We're Keeping An Eye On GT Biopharma's (NASDAQ:GTBP) Cash Burn Rate

Jan 06
We're Keeping An Eye On GT Biopharma's (NASDAQ:GTBP) Cash Burn Rate

GT Biopharma files for $150M mixed shelf offering

Oct 13

We Think GT Biopharma (NASDAQ:GTBP) Needs To Drive Business Growth Carefully

Sep 21
We Think GT Biopharma (NASDAQ:GTBP) Needs To Drive Business Growth Carefully

GT Biopharma GAAP EPS of -$0.10 beats by $0.07

Aug 11

Here's Why We're Watching GT Biopharma's (NASDAQ:GTBP) Cash Burn Situation

Jun 08
Here's Why We're Watching GT Biopharma's (NASDAQ:GTBP) Cash Burn Situation

Companies Like GT Biopharma (NASDAQ:GTBP) Are In A Position To Invest In Growth

Nov 24
Companies Like GT Biopharma (NASDAQ:GTBP) Are In A Position To Invest In Growth

Getting To Know GT Biopharma

Jun 06

GT Biopharma names Gregory Berk Chief Medical Officer

Apr 26

Shareholder Returns

GTBPUS BiotechsUS Market
7D16.3%0.9%0.2%
1Y-68.2%11.0%28.1%

Return vs Industry: GTBP underperformed the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: GTBP underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is GTBP's price volatile compared to industry and market?
GTBP volatility
GTBP Average Weekly Movement13.3%
Biotechs Industry Average Movement11.7%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: GTBP's share price has been volatile over the past 3 months.

Volatility Over Time: GTBP's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
19652Michael Breenhttps://www.gtbiopharma.com

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors.

GT Biopharma, Inc. Fundamentals Summary

How do GT Biopharma's earnings and revenue compare to its market cap?
GTBP fundamental statistics
Market capUS$6.03m
Earnings (TTM)-US$7.60m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GTBP income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$7.60m
Earnings-US$7.60m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-5.50
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did GTBP perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.